Revenue (Tables)

12 Months Ended

Dec. 31, 2020

Revenue

Schedule of reportable segment included under sales category

	2020						2019						2018
(in millions)	U.S.		Int’l		Total		U.S.		Int’l		Total		U.S.		Int’l		Total
Established Pharmaceutical Products —
Key Emerging Markets	$	—	$	3,209	$	3,209	$	—	$	3,392	$	3,392	$	—	$	3,363	$	3,363
Other		—		1,094		1,094		—		1,094		1,094		—		1,059		1,059
Total		—		4,303		4,303		—		4,486		4,486		—		4,422		4,422
Nutritionals —
Pediatric Nutritionals		1,987		2,140		4,127		1,879		2,282		4,161		1,843		2,254		4,097
Adult Nutritionals		1,292		2,228		3,520		1,231		2,017		3,248		1,232		1,900		3,132
Total		3,279		4,368		7,647		3,110		4,299		7,409		3,075		4,154		7,229
Diagnostics —
Core Laboratory		1,166		3,309		4,475		1,086		3,570		4,656		985		3,401		4,386
Molecular		621		817		1,438		149		293		442		152		332		484
Point of Care		369		147		516		438		123		561		432		121		553
Rapid Diagnostics		2,618		1,758		4,376		1,214		840		2,054		1,148		924		2,072
Total		4,774		6,031		10,805		2,887		4,826		7,713		2,717		4,778		7,495
Medical Devices —
Rhythm Management		903		1,011		1,914		1,057		1,087		2,144		1,105		1,093		2,198
Electrophysiology		660		918		1,578		742		979		1,721		678		883		1,561
Heart Failure		547		193		740		574		195		769		467		179		646
Vascular		853		1,486		2,339		1,047		1,803		2,850		1,126		1,803		2,929
Structural Heart		540		707		1,247		616		784		1,400		488		751		1,239
Neuromodulation		564		138		702		660		171		831		690		174		864
Diabetes Care		864		2,403		3,267		678		1,846		2,524		457		1,476		1,933
Total		4,931		6,856		11,787		5,374		6,865		12,239		5,011		6,359		11,370
Other		38		28		66		27		30		57		36		26		62
Total	$	13,022	$	21,586	$	34,608	$	11,398	$	20,506	$	31,904	$	10,839	$	19,739	$	30,578

Schedule of changes in contract liabilities

(in millions)
Contract Liabilities
Balance at December 31, 2018	$	259
Unearned revenue from cash received during the period		411
Revenue recognized related to contract liability balance		(376)
Balance at December 31, 2019		294
Unearned revenue from cash received during the period		505
Revenue recognized related to contract liability balance		(394)
Balance at December 31, 2020	$	405